East China’s Jiangsu province reported a 7.5% year-on-year increase in the added value of the pharmaceutical industry in the first seven months of this year.
Revelutamide, a first-class new drug developed by Lianyungang Hengrui Pharmaceutical was recently approved for marketing, becoming the first self-developed new second-generation androgen receptor inhibitor in China, which will bring a new choice for patients with metastatic prostate cancer.
Nanjing Simcere's anti-coronavirus drug candidate SIM0417 is advancing Phase II and Phase III clinical trials for COVID-19 treatment and close contact prevention.
The anti-tumor drug Dayutong, an anti-tumor drug independently developed by Suzhou-based Innovent Bio for 8 years, was approved for marketing in Indonesia.
This series of exciting new developments in the field of biomedicine in Jiangsu is inseparable from the continuous efforts of the entire industry in R&D investment, system construction, talent introduction and many other links.
As one of the most important sub-sectors in the medical and health field, Jiangsu's medical device industry is also seizing opportunities to seize the high-end market with technological innovation.
In the past, artificial heart valves in the domestic market were monopolized by imported products for a long time.
With continuous efforts to innovate in research and development, Peijia Medical Technology (Suzhou) Co., Ltd. has made breakthroughs in technical aspects such as biological material processing methods and valve sewing techniques. The company has developed two products to overcome aortic valve calcification, effectively solve the difficulty of valve positioning, and further improve the success rate of surgery.
From January to July, these two artificial heart valves accounted for 20% of the national market, stimulating the company's revenue to increase by nearly 130% year-on-year.
Recently, the company has submitted for approval its newly developed third-generation products using biological material processing technology, which is expected to increase the valve’s life to more than 10 years.
The continuous investment in research and development has accelerated the emergence of a large number of innovative achievements, continuously optimizing the industrial structure. In the first half of the year, the province approved 103 new drugs and 165 third-class medical devices, ranking first in the country.
